Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive June 1, 2013 Michele McGovern	Pharmacy Compounding: What's Ahead for Manufacturers Compounders are under increased scrutiny following last year's spinal meningitis outbreak.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
BusinessWeek June 26, 2006 Arlene Weintraub	Homegrown Hormone Therapy: How Safe? Popular alternatives to menopause drugs are under fierce attack by Wyeth and others.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
Searcher June 2012 Stephanie C. Ardito	The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool August 15, 2007 Mary Dalrymple	Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money.
The Motley Fool January 25, 2010 Brian Orelli	No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday.
The Motley Fool May 26, 2011 Brian Orelli	Congress Sets Bad Precedent With AVANIR What happened to free markets?
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
Pharmaceutical Executive July 1, 2014 Jill Wechsler	Pre-emption and States' Rights Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace.
InternetNews June 13, 2005 Roy Mark	Fake Canadian Drug Sites Proliferating New study shows 80 percent of sites claiming to be Canadian drug stores are registered in other countries.
Pharmaceutical Executive April 1, 2009 Patrick Clinton	Dear Commissioner... Unsolicited advice for FDA's next leader: Keep it real, fight popular delusions, and somehow, please, defend the agency.
Fast Company Neal Ungerleider	Why Kim Kardashian's Instagram Post Was In Violation Of FDA Rules Her paid endorsement did not make mandatory statements about Diclegis' side effects and comply with the same rules that require spoken disclaimers at the close of television commercials for prescription drugs.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
Chemistry World November 21, 2014 Rebecca Trager	Ranbaxy sues over withdrawn US approvals Ranbaxy -- India's largest generics manufacturer -- has sued the US Food and Drug Administration after the agency withdrew tentative approval for the company to sell generic versions of two blockbuster drugs
The Motley Fool January 12, 2010 Dayana Yochim	6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab.
The Motley Fool June 11, 2009 Brian Orelli	Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children.
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
Reason September 2005 Kerry Howley	Locking Up Life-Saving Drugs U.S. prescription laws make us sicker and poorer because the system that puts drugs over the counter is driven by profits and patents.
Pharmaceutical Executive May 1, 2011 Jill Wechsler	Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
BusinessWeek December 13, 2004 Carol Marie Cropper	The Inside Dope on Drugs Watchdog Web sites can tip you off to concerns that may not be on the label. Still, before you hit the Net, start with your doctor. And don't overlook the FDA's home page.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
Managed Care July 2000 John Carroll	Physicians Reconsider Taking On Pharmacy Risk They've been burned here in the past, but physicians - and the HMOs that they contract with - may have learned some lessons.
Pharmaceutical Executive July 1, 2009 Jill Wechsler	Safety and Security As FDA looks to balance risks and benefits, more regulations are on the horizon.
Pharmaceutical Executive December 1, 2013	FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
The Motley Fool February 19, 2010 Brian Orelli	Breathe Deep. It Might Not Be That Bad. The FDA strikes down asthma drugs, but will doctors buy in?
BusinessWeek December 22, 2003 Howard Gleckman	Seniors' Big Drug Problem Misusing medications is a leading cause of death among the elderly.
The Motley Fool September 27, 2006 Michael P. Cecil	A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales.
Pharmaceutical Executive October 1, 2010	Pharmacies are Our Friends An underutilized sales resource, pharmacies and their staffs can help lead to improved scrip fulfillment and increased business.
Managed Care March 2005 Martin Sipkoff	Direct-to-Consumer Ads Garner Mixed Outcomes DTC advertising's reputation as a bully may be largely overstated. There's little evidence that sales of specific drugs increase, and there may be some benefit.
Pharmaceutical Executive April 1, 2012 Feam & Lagus	Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.
Managed Care March 2008 Martin Sipkoff	The Epilepsy Battle in the War Between Brands and Generics Brand-name manufacturers and many neurologists see danger in generic substitution, but the FDA insists that the practice is safe
The Motley Fool July 15, 2010 Brian Orelli	The Blockbuster Drug Survives Another Body Blow Avandia is still standing.
Reason Aug/Sep 2001 Jacob Sullum	Through the Nose An FDA advisory committee has voted overwhelmingly to recommend over-the-counter status for Claritin, Allegra, and Zyrtec, three popular prescription allergy drugs. But the drugs' manufacturers are opposing a switch, fearing that it could hurt their profits...
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
Pharmaceutical Executive January 1, 2014 Jill Wechsler	Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing
Pharmaceutical Executive April 1, 2006 Jill Wechsler	Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf?
Pharmaceutical Executive April 10, 2014	Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
Pharmaceutical Executive November 1, 2014 Jill Wechsler	Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system.
Managed Care December 2000	How To Save Money on Prescriptions There are ways for low-income groups to avoid paying top dollar for prescriptions. Here's one way physicians can educate consumers...
The Motley Fool December 4, 2007 Brian Orelli	An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications.
The Motley Fool January 13, 2009 Dayana Yochim	Fiscal Fitness '09: 6 Ways to Score Cheap(er) Drugs Save more than $200 on prescriptions.
Chemistry World June 10, 2014 Anthony King	Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
The Motley Fool December 27, 2004 W.D. Crotty	Drug Safety: Investors Beware Will AstraZeneca become the latest casualty in the drug safety debate?